Plain-English translation of NCT05407324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a clinical trial testing a medication called in people with amyotrophic lateral sclerosis (ALS). The study will compare how well this medication works at two different doses, compared to a placebo, over a 24-week period. If you finish the first part, you may be able to continue taking the medication for up to 2.5 additional years.
ALS is a serious disease that progressively weakens muscles and nerve function. Doctors hope this new treatment may help slow down how quickly the disease progresses and preserve function longer in people living with ALS.
You likely qualify if…
You likely don't qualify if…
In the first part, you will visit a clinic regularly over 24 weeks and take a daily capsule—either the new medication at one of two doses or a placebo. You'll have blood tests and physical exams to monitor how you're doing. If you complete this phase and wish to continue, you can join an extended treatment period lasting up to 2.5 years, during which you will take the medication at a set dose and continue regular check-ins with the research team.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Belgium